health centerscancer center

Enhertu (fam-trastuzumab deruxtecan-nxki)

What is Enhertu, and how does it work?

Enhertu is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received two or more prior anti-HER2 breast cancer treatments.

It is not known if Enhertu is safe and effective in children.

What are the side effects of Enhertu?

WARNING

INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY

  • Interstitial Lung Disease (ILD) and pneumonitis, including fatal cases, have been reported with Enhertu.Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new orworsening respiratory symptoms. Permanently discontinue Enhertu in all patients with Grade 2 or higherILD/pneumonitis. Advise patients of the risk and the need to immediately report symptoms.
  • Embryo-Fetal Toxicity: Exposure to Enhertu during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.

Enhertu can cause serious side effects.

The most common side effects of Enhertu include:

Enhertu may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of Enhertu. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is the dosage for Enhertu?

Recommended Dosage And Schedules

Do Not Substitute Enhertu For Or With Trastuzumab Or Ado-Trastuzumab Emtansine
  • The recommended dosage of Enhertu is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
First Infusion
  • Administer infusion over 90 minutes.
Subsequent Infusions
  • Administer over 30 minutes if prior infusions were well tolerated.
  • Slow or interrupt the infusion rate if the patient develops infusion-related symptoms.
  • Permanently discontinue Enhertu in case of severe infusion reactions.

Dose Modifications

  • Management of adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of Enhertu as described in Tables 1 and 2.
Do Not Re-Escalate The Enhertu Dose After A Dose Reduction Is Made
  • If a planned dose is delayed or missed, administer as soon as possible; do not wait until the next planned cycle.
  • Adjust the schedule of administration to maintain a 3-week interval between doses. Administer the infusion at the dose and rate the patient tolerated in the most recent infusion.

Table 1: Dose Reduction Schedule

Dose Reduction Schedule
(Starting dose is 5.4 mg/kg.)		Dose to be administered
First dose reduction4.4 mg/kg
Second dose reduction3.2 mg/kg
Requirement for further dose reductionDiscontinue treatment

Table 2: Dose Modifications for Adverse Reactions

Adverse ReactionSeverityTreatment Modification
Interstitial Lung Disease (ILD)/pneumonitisAsymptomatic ILD/pneumonitis (Grade 1)Interrupt Enhertu until resolved to Grade 0, then:
  • if resolved in 28 days or less from date of onset, maintain dose.
  • if resolved in greater than 28 days from date of onset, reduce dose one level (see Table 1).
  • consider corticosteroid treatment as soon as ILD/pneumonitis is suspected.
Symptomatic ILD/pneumonitis (Grade 2 or greater)
  • Permanently discontinue Enhertu.
  • Promptly initiate corticosteroid treatment as soon as ILD/pneumonitis is suspected.
NeutropeniaGrade 3 (less than 1.0 to 0.5 x 109/L)
  • Interrupt Enhertu until resolved to Grade 2 or less, then maintain dose.
Grade 4 (less than 0.5 x 109/L)
  • Interrupt Enhertu until resolved to Grade 2 or less.
  • Reduce dose by one level (see Table 1).
Febrile NeutropeniaAbsolute neutrophil count of less than 1.0 x 109/L and temperature greater than 38.3°C or a sustained temperature of 38°C or greater for more than one hour
  • Interrupt Enhertu until resolved.
  • Reduce dose by one level (see Table 1).
Left Ventricular DysfunctionLVEF greater than 45% and absolute decrease from baseline is 10% to 20%
  • Continue treatment with Enhertu.
LVEF 40% to 45%And absolute decrease from baseline is less than 10%
  • Continue treatment with Enhertu.
  • Repeat LVEF assessment within 3 weeks.
And absolute decrease from baseline is 10% to 20%
  • Interrupt Enhertu.
  • Repeat LVEF assessment within 3 weeks.
  • If LVEF has not recovered to within 10% from baseline, permanently discontinue Enhertu.
  • If LVEF recovers to within 10% from baseline, resume treatment with Enhertu at the same dose.
LVEF less than 40% or absolute decrease from baseline is greater than 20%
  • Interrupt Enhertu.
  • Repeat LVEF assessment within 3 weeks.
  • If LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed, permanently discontinue Enhertu.
Symptomatic congestive heart failure (CHF)
  • Permanently discontinue Enhertu.
Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v.4.03).

QUESTION

A lump in the breast is almost always cancer. See Answer

What drugs interact with Enhertu?

No Information Provided

Is Enhertu safe to use while pregnant or breastfeeding?

  • Based on its mechanism of action, Enhertu can cause fetal harm when administered to a pregnant woman.
  • There are no available data on the use of Enhertu in pregnant women.
  • In postmarketing reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death.
  • There is no data regarding the presence of fam-trastuzumab deruxtecan-nxki in human milk, the effects on the breastfed child, or the effects on milk production.
  • Because of the potential for serious adverse reactions in a breastfed child, women should not breastfeed during treatment with Enhertu and for 7 months after the last dose.

Health News

Summary

Enhertu is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received two or more prior anti-HER2 breast cancer treatments. Serious side effects of Enhertu include interstitial lung Disease (ILD) and pneumonitis including fatal cases), and embryo-fetal toxicity.

Multimedia: Slideshows, Images & Quizzes

Related Disease Conditions

  • Breast Cancer
    Breast Cancer

    Breast cancer is an invasive tumor that develops in the mammary gland. Breast cancer is detected via mammograms, breast self-examination (BSE), biopsy, and specialized testing on breast cancer tissue. Treatment of breast cancer may involve surgery, radiation, hormone therapy, chemotherapy, and targeted therapy. Breast cancer risk may be lowered by managing controllable risk factors.

  • Breast Cancer Recurrence
    Breast Cancer Recurrence

    Breast cancer most often recurs within the first 3-5 years after the initial treatment. Changes in the look, feel, or appearance of the breast may indicate breast cancer recurrence. Factors related to recurrence include tumor size, tumor grade, hormone receptor status, lymph node involvement, and oncogene expression. Check out the center below for more medical references on breast cancer, including multimedia (slideshows, images, and quizzes), related diseases, treatment, diagnosis, medications, and prevention or wellness.

  • Triple-Negative Breast Cancer
    Triple-Negative Breast Cancer

    Triple-negative breast cancer is more common in Hispanic and African-American women. Signs and symptoms include a lump in the armpit or breast, nipple discharge and inversion, and changes in the breast's skin. Treatment may incorporate surgery, chemotherapy, and radiation therapy.

  • Breast Cancer Prevention
    Breast Cancer Prevention

    Lifestyle changes, a healthy antioxidant-rich diet, exercise, and weight reduction can help reduce a woman's risk of developing breast cancer. It's important to be aware of how risk factors such as family history, lifestyle factors, breast conditions, radiation therapy, and hormonal factors may influence your chances of developing breast cancer. Mammography and breast self-examinations are crucial steps in breast cancer prevention.

  • Male Breast Cancer
    Male Breast Cancer

    Male breast cancer accounts for 1% of all breast cancers, and most cases are found in men between the ages of 60 and 70. A man's risk of developing breast cancer is one in 1,000. Signs and symptoms include a firm mass located below the nipple and skin changes around the nipple, including puckering, redness or scaling, retraction and ulceration of the nipple. Treatment depends upon staging and the health of the patient.

  • What Questions Should I Ask My Doctor About Breast Cancer?
    What Questions Should I Ask My Doctor About Breast Cancer?

    A diagnosis of breast cancer can be overwhelming, so it's important to write down all your questions before meeting with your doctor.

  • Genetic Testing: Families With Breast Cancer
    Genetic Testing: Families With Breast Cancer

    Breast cancer can be a killer and the decision to get tested to see if a patient is prone to the disease should be discussed with a doctor -- particularly if the woman has a history of breast cancer in her family. Genetic testing can only tell so much about breast cancer risk, however.

  • Breast Cancer Treatment by Stage
    Breast Cancer Treatment by Stage

    Learn about breast cancer treatment at stage 4, 3, 2, 1a, and 0. Discover how breast cancer staging determines a patient's course of treatments. Surgery, radiation therapy, chemotherapy, immunotherapy, hormone therapy, adjuvant HER2-targeted therapy, and neoadjuvant therapy are standard breast cancer treatments.

  • Breast Cancer and Lymphedema
    Breast Cancer and Lymphedema

    Lymphedema is a common chronic, debilitating condition in which excess fluid called lymph collects in tissues and causes swelling in them. It is common after a mastectomy, lumpectomy or breast cancer surgery and radiation therapy.

  • Inflammatory Breast Cancer
    Inflammatory Breast Cancer

    Read about inflammatory breast cancer rash, survival rates, treatment, and diagnosis. Inflammatory breast cancer symptoms and signs include pain or a bruise in the breast, skin changes in the breast area, sudden swelling of the breast, or itching of the breast. Learn more about prognosis, treatments, and diagnosis.

  • Breast Cancer and Coping With Stress
    Breast Cancer and Coping With Stress

    Being diagnosed with breast cancer is stressful. Learning relaxation techniques, exercising, eating well, getting adequate sleep, receiving psychotherapy, and maintaining a positive attitude can help you cope. Creating documents, such as an advance directive, living will, and durable power of attorney will outline your wishes in the event that you are no longer able to make decisions regarding your care.

Treatment & Diagnosis

Doctor's Views

Medications & Supplements

FDA Drug Labels on RxList.com
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

References
All sections courtesy of the U.S. Food and Drug Administration